Progerinin
Phase 2Small molecule
Progerinin is one of 2 small molecule programs targeting Werner syndrome. It is currently in Phase 2.
1
Indications
3
Total Trials
1
Active Trials
1
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1 competitor in Werner Syndrome
#DrugCompanyPhaseTrials
1Genotropin
Eli LillyPreclinical
Progerinin
PPRG Science & Technology Co., Ltd.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Werner syndrome1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Progerinin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details